Compare SANG & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SANG | ANIK |
|---|---|---|
| Founded | 1984 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 172.1M |
| IPO Year | 2018 | 1996 |
| Metric | SANG | ANIK |
|---|---|---|
| Price | $4.72 | $13.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 50.0K | ★ 92.6K |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $112,819,000.00 |
| Revenue This Year | $2.57 | $7.77 |
| Revenue Next Year | $1.61 | $4.22 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.40 | $9.01 |
| 52 Week High | $5.42 | $22.88 |
| Indicator | SANG | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 56.16 | 28.77 |
| Support Level | $4.37 | $11.92 |
| Resistance Level | $4.74 | $15.77 |
| Average True Range (ATR) | 0.10 | 1.27 |
| MACD | -0.00 | -0.39 |
| Stochastic Oscillator | 62.50 | 11.37 |
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic location USA and Other countries. Key revenue is generated from USA.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.